Bedrijfsoverzicht
Design Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on the research, design, development, and commercialization of small molecule therapeutic drugs intended to treat genetic diseases within the United States. The corporation leverages its proprietary GeneTAC platform specifically to design and develop therapeutic candidates, positioning itself within the broader biotechnology sector. Operating in the healthcare industry, the company targets the high-value niche of genetic disease treatments, which often requires significant investment in research and development before commercial realization. As of the latest reporting period, the company holds a market capitalization of $749.93M and employs a workforce of 54 individuals. The market cap figure of $749.93M indicates that the market values the company's intellectual property and pipeline potential at a substantial level despite the lack of traditional revenue streams. The absence of reported annual revenue in the available data suggests the company is still in a pre-revenue or early-stage revenue generation phase typical for clinical-stage biopharma firms. This valuation relative to a small employee base of 54 highlights the capital-intensive nature of the business model, where value is derived from future potential rather than current operational scale.
Financiële gezondheid
The company reports a net income of $-69,792,000 over the trailing twelve months, while EBITDA stands at $-78,445,000, reflecting the heavy costs associated with clinical trials and drug development. The gap between the reported net income and EBITDA figures reveals a significant impact from non-operating expenses, interest, taxes, or other adjustments not captured in the EBITDA metric, which is common for pre-revenue biotechnology firms. Free cash flow for the period is recorded at $-31,311,876, indicating a net outflow of cash required to sustain operations and fund the development pipeline. This negative free cash flow signifies that the company is burning cash to achieve future milestones, which limits immediate financial flexibility but is a standard characteristic of clinical-stage development companies. The gross margin, operating margin, and profit margin are all listed at 0.0%, a metric that indicates the company has not yet generated sufficient revenue to calculate meaningful profitability ratios or has incurred losses that outweigh all revenue generated. The company holds a substantial cash reserve of $219.84M against a relatively minor debt obligation of $1.53M, resulting in a debt-to-equity ratio of 0.72. This balance sheet structure suggests a conservative approach to leverage, as the company's liquidity significantly exceeds its short-term obligations. The current ratio of 17.14 further underscores an exceptionally strong short-term liquidity position, demonstrating the ability to cover current liabilities more than seventeen times over. Return on Equity stands at -30.7% and return on assets is -20.7%, metrics that reveal that management has not yet generated positive returns on the capital deployed, a typical situation for companies still in the research and development phase before product commercialization.
Waarderingsbeoordeling
The trailing twelve-month P/E ratio is listed as N/A due to the lack of net income, whereas the forward P/E is reported at -7.09, a negative figure that implies the market is pricing in future earnings expectations that are currently obscured by present losses. The price-to-book ratio is 3.46, suggesting that the market values the company at more than three times its book value, which typically reflects the high intangible value of the company's intellectual property and pipeline assets rather than its tangible assets. The price-to-sales ratio is N/A because the revenue figure is not available in the financial data, and the EV/EBITDA stands at -6.78, indicating that traditional valuation multiples are distorted by the company's negative earnings and cash flow generation. The stock has traded between a 52-week low of $2.88 and a 52-week high of $12.84, illustrating a wide trading range driven by volatility in the biotechnology sector. Without a specific current price point provided in the source data to calculate the exact percentage deviation, the trading range demonstrates significant price swings relative to the broader market. The beta value is 1.58, which indicates that the stock is significantly more volatile than the broader market, moving 1.58 times as much as the market index on average. This high beta reflects the inherent risk associated with investing in a clinical-stage company with no current product revenue.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both listed as N/A, as the company has not yet generated consistent revenue streams to calculate growth rates. In the absence of positive earnings growth, the company is not reinvesting profits into growth through dividends but rather utilizing its cash reserves to fund operations and development activities. The dividend yield is N/A and the payout ratio is 0.0%, confirming that the company does not distribute any dividends to shareholders. This lack of dividend income is consistent with the company's lifecycle stage, where capital is prioritized for research and development rather than shareholder distributions. Consequently, the overall growth and income profile is defined by capital appreciation potential rather than current income generation or dividend yields.